MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...
3d
Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...
With a shared purpose, we can realize the true promise of CRISPR and improve healthcare, providing hope to more patients with ...
The company could finally be ready to deliver on years of promise.
Add Yahoo as a preferred source to see more of our stories on Google. Stanford researchers have developed CRISPR-GPT, an AI-powered copilot that guides gene-editing experiments. (CREDIT: Shutterstock) ...
Antibiotic resistance is racing toward a global crisis, with “superbugs” projected to cause over 10 million deaths annually ...
On a special episode (first released on June 20, 2024) of The Excerpt podcast: With the advent of CRISPR as a gene editing technology, there are new opportunities to develop breakthrough treatments ...
CRISPR gene editing revolutionized the cell and gene therapy (CGT) industry this past decade, but the industry still faces significant bottlenecks and gaps between development and manufacturing that ...
In a groundbreaking fusion of artificial intelligence and gene editing, researchers are leveraging machine learning to enhance CRISPR technology’s precision and efficiency. This integration is opening ...
Let's check out two exciting biotech stocks that may climb 58% and 200%, according to Wall Street. Image source: Getty Images ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results